US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.08 — a miss of 50.0%.
Analysts rate Gyre Therapeutics Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $18.67.
| Fund | Stake |
|---|---|
| HSG Holding Ltd | 3.54% |
| BlackRock Inc | 0.94% |
| Octagon Capital Advisors LP | 0.90% |
| Vanguard Capital Management, LLC | 0.83% |
| Geode Capital Management, LLC | 0.50% |
| State Street Corp | 0.23% |
| Charles Schwab Investment Management Inc | 0.17% |
| Northern Trust Corp | 0.16% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • On October 16, 2026, Gyre Therapeutics entered into employment agreements allowing Ying Luo, Ph.D. to continue as Chief Execut | 2026-10-22 |
| Reg FD disclosure · Q3 2026 GYRE THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or numerical metrics disclosed in this filing • Document date: Se | 2026-09-01 |
| Reg FD disclosure · Q3 2026 GYRE THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company filed Form 8-K on August 26, 2026 • Trading symbol: GYRE on Nasdaq Capital Mar | 2026-08-26 |
| Quarterly report · Q2 2026 GYRE THERAPEUTICS, INC. - 10-Q SUMMARY FOR RETAIL INVESTORS Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $43.3 million in cash | 2026-08-07 |
| Results announced · Q3 2026 GYRE THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $29.1 million (down 2% vs. $29.7 million in Q2 2025) • Q2 2026 GAAP | 2026-08-07 |
| Board / officer change · Q3 2026 GYRE THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Gyre Therapeutics, Inc. (Nasdaq: GYRE) • Report Date: July 10, 2026 • Headqua | 2026-07-16 |
| Quarterly report · Q1 2026 GYRE THERAPEUTICS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS Q1 2026 (Period Ended March 31, 2026) --- HEADLINE NUMBERS • Revenue Q1 2026: $22.5 mil | 2026-05-08 |
| Proxy statement · Q2 2026 GYRE THERAPEUTICS, INC. — PROXY STATEMENT SUMMARY CEO COMPENSATION • Ping Zhang (Interim CEO and Executive Chairman): Total compensation figure not | 2026-04-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gyre Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.